Evommune (EVMN) Long-Term Investments (2025 - 2026)
Evommune's (EVMN) quarterly Long-Term Investments came in at $95.5 million in Q1 2026, up 41.58% on a QoQ basis from $67.5 million in Q4 2025.
Evommune (EVMN) Long-Term Investments (2025 - 2026) Analysis & Trends
Evommune (EVMN) has 2 years of Long-Term Investments data on file, last reported at $95.5 million in Q1 2026.
- On a quarterly basis, Long-Term Investments changed N/A year-over-year to $95.5 million in Q1 2026; TTM through Mar 2026 was $95.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $67.5 million, changed N/A from the prior year.
- Long-Term Investments for Q1 2026 stood at $95.5 million, up from $67.5 million in the prior quarter.
- Over the last five years, Long-Term Investments for EVMN reached as high as $95.5 million in Q1 2026 and fell as low as $67.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Evommune | 381.48 Mn | 170.02 Mn | - | 95.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95.55 Mn |
| Dec 31, 2025 | 67.49 Mn |